AVDL vs SUPN vs JAZZ vs AXSM vs INVA

For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.

8% revenue growth year-over-year, versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Avadel Pharmaceuticals plc (AVDL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Innoviva, Inc.

is actually cheaper at 7. 3x.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +286. 4%, compared to +30. 0% for Jazz Pharmaceuticals plc (JAZZ). Over 10 years, the gap is even starker: AXSM returned +1862% versus JAZZ's +52. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus Supernus Pharmaceuticals, Inc. 's 0. 80β — meaning SUPN is approximately 604% more volatile than INVA relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.

8% versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, AXSM leads at 133. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -28. 9% for Avadel Pharmaceuticals plc — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -26. 5% for AXSM. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 7. 3x forward P/E versus 28. 3x for Avadel Pharmaceuticals plc — 21. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 75. 4% to $40. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 67), +1862% 10Y return). Both have compounded well over 10 years (AXSM: +1862%, JAZZ: +52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AVDL is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock; JAZZ is a mid-cap quality compounder stock; AXSM is a mid-cap high-growth stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.